A major acquisition has taken place in the Dallas biopharmaceutical scene. Forte Biosciences Inc, a company based in Dallas, has been acquired by a pharmaceutical firm from the Netherlands. The acquisition price was $2.2 billion.

The acquiring company, Argenx, is looking to expand its portfolio with Forte Biosciences' experimental drug. This move is part of Argenx's goal to become a leading innovator in immunology. Further details about the acquisition and its implications are available from the source.

The deal highlights significant activity in the North Texas biopharmaceutical industry, with local companies attracting major investments from international firms.